A detailed history of Vanguard Group Inc transactions in 4 D Molecular Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,339,943 shares of FDMT stock, worth $55.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,339,943
Previous 1,866,849 25.34%
Holding current value
$55.7 Million
Previous $37.8 Million 97.11%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$17.03 - $35.87 $8.06 Million - $17 Million
473,094 Added 25.34%
2,339,943 $74.6 Million
Q4 2023

Feb 14, 2024

SELL
$9.76 - $21.25 $347,631 - $756,882
-35,618 Reduced 1.87%
1,866,849 $37.8 Million
Q3 2023

Nov 14, 2023

SELL
$12.64 - $19.76 $892,826 - $1.4 Million
-70,635 Reduced 3.58%
1,902,467 $24.2 Million
Q2 2023

Aug 14, 2023

BUY
$15.16 - $23.26 $6.48 Million - $9.94 Million
427,218 Added 27.64%
1,973,102 $35.7 Million
Q1 2023

May 15, 2023

BUY
$15.45 - $23.19 $4.23 Million - $6.35 Million
273,674 Added 21.51%
1,545,884 $26.6 Million
Q4 2022

Feb 10, 2023

SELL
$6.85 - $25.46 $329,841 - $1.23 Million
-48,152 Reduced 3.65%
1,272,210 $28.3 Million
Q3 2022

Nov 14, 2022

SELL
$6.96 - $11.48 $12,437 - $20,514
-1,787 Reduced 0.14%
1,320,362 $10.6 Million
Q2 2022

Aug 12, 2022

BUY
$5.68 - $15.99 $177,261 - $499,015
31,208 Added 2.42%
1,322,149 $9.23 Million
Q1 2022

May 13, 2022

BUY
$13.16 - $22.64 $103,411 - $177,905
7,858 Added 0.61%
1,290,941 $19.5 Million
Q4 2021

Feb 14, 2022

BUY
$19.56 - $32.94 $6.59 Million - $11.1 Million
337,106 Added 35.64%
1,283,083 $28.2 Million
Q3 2021

Nov 12, 2021

BUY
$22.73 - $36.04 $10.8 Million - $17.1 Million
475,701 Added 101.15%
945,977 $25.5 Million
Q2 2021

Aug 13, 2021

BUY
$22.2 - $42.29 $10.4 Million - $19.9 Million
470,276 New
470,276 $11.3 Million

Others Institutions Holding FDMT

About 4D Molecular Therapeutics, Inc.


  • Ticker FDMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,382,400
  • Market Cap $771M
  • Description
  • 4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical tr...
More about FDMT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.